22UA.F Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 18:23):

Stats
Dagens volum	747.00
Gjennomsnittsvolum	1 322.00
Markedsverdi	19.61B
EPS	€0 ( 2024-03-20 )
Neste inntjeningsdato	( €11.56 ) 2024-05-05
Last Dividend	€2.13 ( 2022-06-02 )
Next Dividend	€0 ( N/A )
P/E	21.54
ATR14	€0.412 (0.50%)

BioNTech SE Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

BioNTech SE Økonomi

Annual	2023
Omsetning:	€3.82B
Bruttogevinst:	€3.22B (84.29 %)
EPS:	€3.79

FY	2023
Omsetning:	€3.82B
Bruttogevinst:	€3.22B (84.29 %)
EPS:	€3.79

FY	2022
Omsetning:	€17.31B
Bruttogevinst:	€12.78B (73.82 %)
EPS:	€38.08

FY	2021
Omsetning:	€18.98B
Bruttogevinst:	€15.12B (79.66 %)
EPS:	€40.63

Financial Reports:

No articles found.

BioNTech SE Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

BioNTech SE Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.73 - good (97.30%) | Divividend Growth Potential Score: 2.39 - No dividend growth expected in the near future

Information

First Dividend	€2.13	2022-06-02
Last Dividend	€2.13	2022-06-02
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	€2.13	--
Avg. Dividend % Per Year	0.00%	--
Score	1.83	--
Div. Sustainability Score	9.73
Div.Growth Potential Score	2.39
Div. Directional Score	6.06	--

Next Divdend (Est)
(2024-04-27)

€0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.83

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
KHNZ.DE	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
TLX.DE	Ex Dividend Junior	2023-05-05	Annually	0.00%
DUE.DE	Ex Dividend Junior	2023-05-15	Annually	0.00%
MTX.DE	Ex Dividend Junior	2023-05-12	Annually	0.00%
ABL.DE	Ex Dividend Knight	2023-10-12	Quarterly	0.00%
WCH.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
FPE3.DE	Ex Dividend Knight	2023-05-04	Annually	0.00%
PAT.DE	Ex Dividend Junior	2023-05-26	Sporadic	0.00%
AXA.DE	Ex Dividend Junior	2023-05-08	Sporadic	0.00%
HHFA.DE	Ex Dividend Junior	2023-06-16	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.244	1.500	5.13	7.69	[0 - 0.5]
returnOnAssetsTTM	0.0404	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0464	1.500	-0.596	-0.894	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.43	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	9.12	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	5.63	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00952	-1.500	9.84	-10.00	[0 - 0.6]
interestCoverageTTM	5.58	1.000	9.04	9.04	[3 - 30]
operatingCashFlowPerShareTTM	22.59	2.00	2.47	4.94	[0 - 30]
freeCashFlowPerShareTTM	19.63	2.00	0.186	0.373	[0 - 20]
debtEquityRatioTTM	0.0108	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.527	1.000	4.54	4.54	[0.2 - 0.8]
operatingProfitMarginTTM	0.181	1.000	8.38	8.38	[0.1 - 0.6]
cashFlowToDebtRatioTTM	24.52	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.166	0.800	-2.23	-1.781	[0.5 - 2]
Total Score				9.73

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	21.08	1.000	7.97	0	[1 - 100]
returnOnEquityTTM	0.0464	2.50	-0.383	-0.894	[0.1 - 1.5]
freeCashFlowPerShareTTM	19.63	2.00	3.46	0.373	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	22.59	2.00	2.47	4.94	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	1.406	1.000	10.00	0	[0.1 - 0.5]
Total Score				2.39

BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.